Luseogliflozin for the treatment of type 2 diabetes

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 18, 2014, Pages 2741-2749

  Seino, Yutaka ^a  

^a KANSAI ELECTRIC POWER CO   (Japan)

Author keywords

Luseogliflozin; Sodium glucose cotransport; Sodium glucose cotransporter 2 inhibitor; Type 2 diabetes mellitus

Indexed keywords

LUSEOGLIFLOZIN; PLACEBO; 1,5-ANHYDRO-1-(5-(4-ETHOXYBENZYL)-2-METHOXY-4-METHYLPHENYL)-1-THIOGLUCITOL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; SODIUM GLUCOSE COTRANSPORTER 2; SORBITOL;

ARTICLE; BLOOD PRESSURE; BODY WEIGHT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; KIDNEY DISEASE; LIVER DYSFUNCTION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); ANALOGS AND DERIVATIVES; ANALYSIS; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; HALF LIFE TIME; METABOLISM;

BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2; SORBITOL;

EID: 84910685028     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.978290     Document Type: Article

References (31)

1. International Diabetes Federation. IDF Diabetes Atlas. 6th edition. Available from: http://www.idf.org/diabetesatlas/[Last accessed 29 January 2014]
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35: 1364-79
3. Garber AJ, Abrahamson M, Barzilay J, et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement. Endocr Pract 2013;19: 536-57
4. Qaseem A, Humphrey LL, Sweet DE, et al. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2012;156: 218-31
5. Ahren B. DPP-4 inhibition and islet function. J Diabetes Investig 2012;3: 3-10
6. Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagonlike peptide-1: incretin actions beyond the pancreas. J Diabetes Investig 2013;4: 108-30
7. Zoungas S, Chalmers J, Ninomiya T, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 2012;55: 636-43
8. Clar C, Gill JA, Court R, et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012;2: e001007
9. Yamamoto K, Uchida S, Kitano K, et al. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with antihyperglycaemic activity. Br J Pharmacol 2011;164: 181-91
10. Musso G, Gambino R, Cassader M, et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-Transport (SGLT) inhibitors: systematic review and meta-Analysis of randomized trials. Ann Med 2012;44: 375-93
11. Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol Ther 2013;139: 51-9
12. Acquisition of manufacturing and marketing approval in Japan for SGLT2 inhibitor Lusefi-Tablets 2.5 mg and Lusefi-Tablets 5 mg [media release]. Taisho Pharmaceutical Holdings Co., Ltd., Tokyo; 2014. Available from: http://www.taishoholdings. co.jp/en/release/2014/2014032401-e.pdf [Last accessed 8 August 2014]
13. Kakinuma H, Oi T, Hashimoto-Tsuchiya Y, et al. (1S)-1, 5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-Thio-Dglucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem 2010;53: 3247-61
14. Lusefi-Tablets 2.5/5 mg package insert. Tokyo: Taisho Pharmaceutical Co., Ltd., 2014. Available from: http://www.info. pmda.go.jp/go/pack/3969020F1020-1-01/[Last accessed 12 August 2014]; In Japanese
15. Chino Y, Hasegawa M, Hachiuma K, et al. Pharmacokinetics and prediction of drug-drug interaction of TS-071 a selective SGLT2 inhibitor. 26th JSSX Annual Meeting; 16-18 November 2011; Hiroshima, Japan;. Poster Session 2-P2-28
16. Miyata A, Hasegawa M, Mori H, et al. Characterization of the human enzymes involved in the metabolism of luseogliflozin (TS-071), a selective SGLT2 inhibitor. 28th JSSX Annual Meeting; 9-11 October 2013; Tokyo, Japan; Poster Session 2-G-P-17
17. The pharmaceutical interview form, supplemental to the package insert for Lusefi-Tablets 2.5/5 mg. Tokyo: Taisho Pharmaceutical Co., Ltd., 2014. Available from: http://www.info. pmda.go.jp/go/pack/3969020F1020-1-01/[Last accessed 12 August 2014]; In Japanese
18. Sasaki T, Seino Y, Fukatsu A, et al. Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy japanese males: a randomized, single-blind, placebo-controlled trial. Adv Ther 2014;31: 345-61
19. Sasaki T, Seino Y, Fukatsu A, et al. TS-071, a novel potent and highly selective renal sodium-glucose co-Transporter 2 (SGLT2) inhibitor, increases urinary glucose excretion and reduces plasma glucose levels in Japanese patients with type 2 diabetes mellitus. 47th European Association for the Study of Diabetes (EASD) Annual Meeting; 12-16 September 2011; Lisbon, Portugal; Poster 846
20. Sasaki M.,Seino Y.,Samukawa Y, et al. Effects of gender and age on the pharmacokinetics and pharmacodynamics of luseogliflozin (TS-071), a selective SGLT2 inhibitor 72nd Scientific Sessions of the American Diabetes Association 8-12 June 2012; Philadelphia, PA, USA; Poster 1069-p
21. Haneda M., Seino Y., Sasaki T., et al. Luseogliflozin (TS-071), a selective SGLT2 inhibitor, improves glycemic control in Japanese type 2 diabetic subjects with renal impairment 48th European Association for the Study of Diabetes (EASD Annual Meeting; 1-5 October 2012; Berlin, Germany; Poster 741
22. Seino Y, Sasaki T, Fukatsu A, et al. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin 2014;30: 1245-55
23. Seino Y, Sasaki T, Fukatsu A, et al. Luseogliflozin, a selective SGLT2 inhibitor, improves glycemic control as monotherapy in Japanese patients with T2DM. International Diabetes Federation 2013 World Diabetes Congress; 2-6 December 2013; Melbourne, Australia; Poster P-1472
24. Sasaki T, Seino Y, Fukatsu A, et al. Consistent efficacy of add-on combination of luseogliflozin with conventional oral antidiabetic drugs in Japanese patients with T2DM. International Diabetes Federation 2013 World Diabetes Congress; 2-6 December 2013; Melbourne, Australia; Poster P-1471
25. Johnsson KM, Ptaszynska A, Schmitz B, et al. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27: 473-8
26. Johnsson KM, Ptaszynska A, Schmitz B, et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27: 479-84
27. Launch of Suglat-Tablets, a selective SGLT2 inhibitor for treatment of type 2 diabetes-first SGLT2 Inhibitor in Japan, providing new options in the treatment of type 2 diabetes [media release]. Astellas Pharma Inc., Tokyo. Available from: http://www.astellas.com/en/corporate/news/detail/launch-of-suglattablets-A-sel.html [Last accessed 12 August 2014]
28. Forxiga-receives regulatory approval in Japan for the treatment of type 2 diabetes [media release]. Ono Pharmaceutical Co., Ltd., Osaka, AstraZeneca, London. Available from: http://www.astrazeneca.com/Media/Pressreleases/Article/20140324-forxiga-japanapproval [Last accessed 12 August 2014]
29. Poole RM, Prossler JE. Tofogliflozin: first global approval. Drugs 2014;74: 939-44
30. Marketing and manufacturing approval in Japan received for Canaglu-Tablets 100 mg [media release]. Mitsubishi Tanabe Pharma Corporation, Osaka; Daiichi Sankyo Co., Ltd., Tokyo. Available from: http://www.mt-pharma. co.jp/e/release/nr/2014/pdf/e-MTPC140704.pdf [Last accessed 25 August 2014]
31. Seino Y, Sasaki T, Fukatsu A, et al. Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, doubleblind, placebo-controlled, phase II study. Curr Med Res Opin 2014;30: 1231-44